Jim Cramer Discusses These 13 Stocks & Rejects The AI PC Super Cycle

Page 5 of 12

8. Johnson & Johnson (NYSE:JNJ)

Number of Hedge Fund Holders In Q3 2024: 81

Johnson & Johnson (NYSE:JNJ) is a well-known global healthcare and pharmaceutical company. Its scale means that even though the firm has faced headwinds from a multi-billion dollar cancer lawsuit in 2024, it has managed to comfortably chug along by delivering through its cancer medicine business. However, Johnson & Johnson (NYSE:JNJ)’s medical device business struggled in 2024 as its Q1 2024 medical device sales of $7.82 billion missed analyst estimates of $7.88 billion. In Q3, Johnson & Johnson (NYSE:JNJ)’s cancer drug sales jumped by 19% worldwide. The firm maintained momentum in Q4 as its midpoint 2025 sales guidance of $91.3 billion beat analyst estimates of $90.98 billion. Cramer believes that the market is treating Johnson & Johnson (NYSE:JNJ)’s stock unfairly:

“Now JNJ, people were bummed. I wasn’t as bummed as people. The other people, but I think we get some rollbacks.”

Page 5 of 12